Understanding Tysabri and PML: A Research Update on Long-Term Monitoring
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
Legacy of General Health Information and the Shift to Occupational Exposure Concerns
If you or a loved one has taken Tysabri for multiple sclerosis or Crohn's disease, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. Over the years, as Tysabri use has expanded, clinical research has shifted from initial efficacy studies to long-term safety surveillance, providing critical insights into PML risk factors and monitoring strategies. This page reviews current research updates on Tysabri-related PML, including symptom timelines and follow-up recommendations.
Medical Evidence: Tysabri and Progressive Multifocal Leukoencephalopathy
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Illinois who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations—is essential. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus and typically occurs only in immunocompromised individuals. The FDA identifies three key risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy. The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, vision loss, and speech difficulties. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The FDA advises healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to withhold dosing immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite monitoring, PML can progress rapidly, leading to severe disability or death. Adverse event reports from the FDA Adverse Event Reporting System (FAERS) frequently associate Tysabri with symptoms that overlap with PML, including fatigue (19,150 reports), gait disturbance (9,422 reports), balance disorder (5,621 reports), muscular weakness (4,535 reports), and cognitive disorder (3,478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports underscore the importance of prompt evaluation for PML when such symptoms emerge.
Mechanistic Pathways and Risk Considerations
Tysabri is a monoclonal antibody that binds to alpha-4 integrin, blocking lymphocyte adhesion and migration into the central nervous system. This mechanism reduces neuroinflammation in multiple sclerosis but also impairs immune surveillance against JC virus. In immunocompromised patients, JC virus can reactivate and infect oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk is highest in patients with anti-JCV antibodies, prolonged therapy, or prior immunosuppressant use, as these factors further compromise immune control of the virus. The FDA boxed warning clearly states that Tysabri increases PML risk and that the drug is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether patients received adequate information about the magnitude of risk, the specific risk factors, and the importance of early symptom reporting. For affected patients, the adequacy of warnings can be a central issue in legal claims.
Statute of Limitations for Tysabri Claims in Illinois
In Illinois, the statute of limitations for personal injury claims, including those related to pharmaceutical injuries, is generally two years from the date the injury was discovered or should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can vary. PML may develop months to years after starting Tysabri, and symptoms may initially be subtle. The discovery date is critical: it is the point at which a patient or their family reasonably knew or should have known that PML was caused by Tysabri. This could be the date of diagnosis, the date of a positive JC virus test, or the date when a physician first linked symptoms to the drug. Patients and families should consult an attorney experienced in pharmaceutical litigation to evaluate their specific timeline. Factors such as the duration of Tysabri use, the presence of anti-JCV antibodies, and prior immunosuppressant use may influence the strength of a claim. Additionally, the TOUCH program's monitoring requirements may be relevant if a healthcare provider failed to follow recommended screening or symptom evaluation protocols.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri-related PML claims in Illinois?
In Illinois, the statute of limitations for personal injury claims, including those related to pharmaceutical injuries, is generally two years from the date the injury was discovered or should have been discovered. For PML, the discovery date is critical and may be the date of diagnosis or when a physician first linked symptoms to Tysabri.
What are the key risk factors for developing PML while on Tysabri?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.